Trial Profile

A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 03 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aficamten (Primary)
Indications Hypertrophic cardiomyopathy
Focus Adverse reactions
Acronyms FOREST-HCM; FOREST-HCM CMR; REDWOOD-HCM OLE
Sponsors Cytokinetics

Most Recent Events

11 May 2026 According to Cytokinetics media release, data from this study were presented at the European Society of Cardiology (ESC) Heart Failure 2026 Congress.
11 May 2026 Results presented in a Cytokinetics Media Release.
05 May 2026 According to Cytokinetics media release, data from the trial were presented at the American College of Cardiology (ACC) Annual Scientific Session & Expo

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com